| This week's sponsor is FierceBiotech’s Drug Development Forum. | | FierceBiotech’s Drug Development Forum – September 19-21, 2016 Join leading biotech professionals in the first-ever Drug Development Forum in Boston. Discover the latest trends, challenges, and innovations in the biotech industry. Sign up by July 29, 2016 and save $200 on registration.
Register now |
Top Stories Wednesday, July 6, 2016 Carmot Therapeutics has secured its second major partnership. The latest is a discovery and licensing deal with Roche’s Genentech. Wednesday, July 6, 2016 Taking a look back at its Genzyme acquisition handbook, Sanofi has turned to CVRs as its new ploy to buy out its highly desired biotech target Medivation--but it will have to get in line as the company opens itself up to other suitors. Tuesday, July 5, 2016 Only 12 IPOs made it out last quarter from U.S. venture-backed companies. Of those, 9 were for biotech companies. That’s just one of the measures showing that biotech has held up relatively well despite a volatile stock market, at least as compared to its information technology peers. Wednesday, July 6, 2016 Pfizer and research partner Merck KGaA have begun late-stage testing of their experimental checkpoint inhibitor avelumab with chemo in certain ovarian cancer patients. Wednesday, July 6, 2016 XBiotech tried to talk up a questionable colon cancer trial as being positive, but investors were having none of it as its shares tanked by nearly 50% yesterday. Wednesday, July 6, 2016 GenSight Biologics is looking to bounce back from its failure to list on Nasdaq by pulling off an IPO in its home city of Paris. The Novartis-backed gene therapy player has downsized its ambitions in moving back across the Atlantic, with the currently-targeted IPO haul of €40 million coming in well below the $100 million it first set out to raise on Nasdaq. Tuesday, July 5, 2016 It’s an awkward age, to be 15. But that’s exactly where we are with the Fierce 15 this year. | | | Sanofi Genzyme has started a pivotal Phase II/III trial of olipudase alfa for patients with sphingomyelinase deficiency. Release The FDA has granted Merrimack a fast-track designation for its seribantumab in non-small cell lung cancer. Statement A new NIH-funded center has been set up to study inefficiencies in clinical trials. Release | |
|
Resources Sponsored by: SDC Interested in intended use validation of SaaS-based EDC systems? Prefer to discuss rescue study strategies and considerations? How about understanding statistical power for non-statisticians? Vote for your favorite webinar topic to be presented by SDC at DIA on June 28, 2016, 12pm EDT. Cast Your Vote Here to receive your exclusive event invitation and a recording of the webinar after the event. Sponsored by: Covance Al Blunt, MD, Executive Medical Director, Oncology at Covance discusses how the lessons learned from the past decade of developing targeted therapies are relevant to the future development of cancer immunotherapy. Download today! Sponsored by: Veeva Systems Gartner research on short- and long-term strategies for IDMP compliance. |
|
